AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis

UC Is Final Planned Indication For IL-23 Inhibitor

 
• By Mandy Jackson
  
Check marks on four wooden blocks
Ulcerative colitis is the fourth and final indication for Skyrizi • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D